Renjith Vijayakumar Selvarani, Founder, Chairman, Chief Scientific and Technology Officer at OLUSIUM, shared a post on LinkedIn:
“Reprogramming Cancer: Turning Deadly Cells Back to Normal?
Imagine a future where we don’t destroy cancer cells with toxic treatments… we simply reprogram them to behave like normal, healthy cells again. That future just got one giant step closer.
Researchers at the 한국과학기술원(KAIST) have developed a pioneering approach that reverses colon cancer cells into a normal-like state by targeting three key genetic ՛master regulators՛: MYB, HDAC2, and FOXA2.
Instead of chemotherapy or radiation that harms healthy tissue, this method restores cell identity, leaving healthy cells untouched.
- Validated through digital modeling, laboratory experiments, and mouse studies
- No damage to surrounding healthy tissue
- Introduces the groundbreaking concept of reversible cancer therapy
Even more promising: the team successfully applied the same principle to brain cell models, opening the door to potential treatments for brain cancer as well.
Lead researcher Professor Kwang-Hyun Cho emphasized:
՛This research introduces the novel concept of reversible cancer therapy by reverting cancer cells to normal cells. It could pave the way for more precise, less invasive treatments.՛
This is a paradigm shift from killing cancer to restoring order.
Huge congratulations to the entire KAIST team! This could transform oncology and spare millions from the brutal side effects of current treatments.
Proper Reference: KAIST Official News (December 2024)”
Title: Control of Cellular Differentiation Trajectories for Cancer Reversion
Authors: Jeong-Ryeol Gong, Chun-Kyung Lee, Hoon-Min Kim, Juhee Kim, Jaeog Jeon, Sunmin Park, Kwang-Hyun Cho
Read the Full Article.
Other articles featuring Renjith Vijayakumar Selvarani on OncoDaily.